KAPITEL 3 Leukozytenapherese
JEDNS LIEBE - Chronisch entzündliche Darmerkrankungen …, 2013 - books.google.com
In den vergangenen 15 Jahren wurden schon mehrfach Methoden der Zellapherese im
Rahmen der Therapie von chronisch entzündlichen Darmerkrankungen angewendet. Dabei …
Rahmen der Therapie von chronisch entzündlichen Darmerkrankungen angewendet. Dabei …
Leukocytapheresis in the treatment of inflammatory bowel disease: Current position and perspectives
P Vernia, V D'Ovidio, D Meo - Transfusion and Apheresis Science, 2010 - Elsevier
Therapeutic apheresis, a novel approach for immunodisorders, has been used in the last
decade for the treatment of ulcerative colitis with promising result, and represents an …
decade for the treatment of ulcerative colitis with promising result, and represents an …
Apheresis in inflammatory bowel disease
P Nos, E Domenech - Gastroenterologia y Hepatologia, 2009 - europepmc.org
Apheresis systems have been used in inflammatory bowel disease with a view to
immunomodulation. The technique employs a system of white cell extraction, filtration and …
immunomodulation. The technique employs a system of white cell extraction, filtration and …
Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia
T Ljung, O Østergaard Thomsen, M Vatn… - Scandinavian journal …, 2007 - Taylor & Francis
Objective. Selective leukocyte apheresis is a new type of non-pharmacological treatment for
patients with active ulcerative colitis and Crohn's disease. Preliminary data have indicated …
patients with active ulcerative colitis and Crohn's disease. Preliminary data have indicated …
Leukozytenapherese bei Patienten mit chronisch aktiver Colitis ulcerosa
J Emmrich, H Prophet, G Waitz… - Zeitschrift für …, 2009 - thieme-connect.com
Ziele: In einer Pilotstudie sollte die Wirksamkeit der Leukozytenapherese unter Verwendung
einer neuen Celluloseverbindung (GranuWash®, Membrana GmbH, Wuppertal)) bei …
einer neuen Celluloseverbindung (GranuWash®, Membrana GmbH, Wuppertal)) bei …
[PDF][PDF] Current status on the clinical usefulness of apheresis in patients with inflammatory bowel disease
JK Triantafillidis, P Cherakakis - Annals of Gastroenterology, 2003 - 172.104.143.169
In this review the current aspects concerning the application of leukocytapheresis in patients
with inflammatory bowel disease are briefly discussed. Leukocytapheresis has already been …
with inflammatory bowel disease are briefly discussed. Leukocytapheresis has already been …
Developments in the apheresis procedure for the treatment of inflammatory bowel disease
AA Pineda - Inflammatory bowel diseases, 2006 - academic.oup.com
Initially used to treat rheumatoid arthritis, nonselective therapeutic leukocytapheresis was
applied to the treatment of inflammatory bowel disease (IBD) as early as the 1980s. Since …
applied to the treatment of inflammatory bowel disease (IBD) as early as the 1980s. Since …
[PDF][PDF] therapie der chronisch aktiven Colitis ulcerosa mit der Granulozyten, Monozyten Apherese
B Friemel - rosdok.uni-rostock.de
Die Colitis ulcerosa als eine Form der chronisch entzündlichen Darmerkrankungen ist
bedingt durch Störungen der intestinalen Immunregulation. Die zellulören Vorgönge sind …
bedingt durch Störungen der intestinalen Immunregulation. Die zellulören Vorgönge sind …
Leukocytapheresis as promising therapy for inflammatory bowel disease
R Caprilli, V D'Ovidio - Digestive and liver disease, 2007 - dldjournalonline.com
Leukocytapheresis, device used to remove leukocytes from peripheral circulation, has been
approved for the treatment of active ulcerative colitis (UC) by the Ministry of Health and …
approved for the treatment of active ulcerative colitis (UC) by the Ministry of Health and …
Cytapheresis in inflammatory bowel diseases: current evidence and perspectives
S Danese, E Angelucci, T Stefanelli, P Omodei… - Digestion, 2008 - karger.com
Ulcerative colitis and Crohn's disease are inflammatory bowel diseases with a chronic
relapsing course. Management of both conditions is far from being fully satisfactory. For this …
relapsing course. Management of both conditions is far from being fully satisfactory. For this …